Distribution and Analysis of Metastatic Lymph Nodes in Colorectal Cancer Patients (DIAMOND) (NCT07306390) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Distribution and Analysis of Metastatic Lymph Nodes in Colorectal Cancer Patients (DIAMOND)
China1,200 participantsStarted 2026-07-01
Plain-language summary
The goal of this observational study is to learn about the spatial distribution and significance of metastatic lymph nodes in colorectal cancer patients. The main question it aims to answer is:
* What is the spatial distribution pattern of metastatic lymph nodes in patients with colorectal cancer?
* Can the spatial distribution pattern of metastatic lymph nodes in patients with colorectal cancer guide clinical practice? Participants should undergo regular follow-up examinations for at least 5 years after the surgery.
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Aged between 18 and 80 years
* Pathologically confirmed adenocarcinoma of the colon or rectum
* Underwent radical resection for colorectal cancer with a D3 lymphadenectomy and lymph nodes were submitted for pathological examination according to standardized station-based and distance-based protocol
* No distant metastasis or distant metastasis within 6 months after surgery
* No history of other malignant tumors or severe systemic diseases
* No immune diseases or inflammatory bowel diseases
* Non-emergency surgery
* With complete clinicopathological and follow-up data
Exclusion Criteria:
* Pathologically confirmed benign tumors or non-adenocarcinoma malignancies
* Underwent local excision or palliative resection
* Regional lymph nodes were not dissected or submitted for pathological examination according to the unified station-based or distance-based protocol
* With distant metastasis or distant metastasis within 6 months after surgery
* Dual or multiple primary colorectal cancers or concurrent other malignant tumors
* Had a previous diagnosis of immune diseases or inflammatory bowel disease such as ulcerative colitis or Crohn's disease
* Underwent emergency surgery
* Had incomplete clinicopathological or follow-up data
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
The spatial distribution of metastatic lymph nodes
Timeframe: From enrollment to 14 days after surgery (at the completion of postoperative pathological examination)
Trial details
NCT IDNCT07306390
SponsorCancer Institute and Hospital, Chinese Academy of Medical Sciences